Metformin and cognition from the perspectives of sex, age, and disease

Kiran Chaudhari, Conner D. Reynolds, Shao Hua Yang

Research output: Contribution to journalReview article

Abstract

Metformin is the safest and the most widely prescribed first-line therapy for managing hyperglycemia due to different underlying causes, primarily type 2 diabetes mellitus. In addition to its euglycemic properties, metformin has stimulated a wave of clinical trials to investigate benefits on aging-related diseases and longevity. Such an impact on the lifespan extension would undoubtedly expand the therapeutic utility of metformin regardless of glycemic status. However, there is a scarcity of studies evaluating whether metformin has differential cognitive effects across age, sex, glycemic status, metformin dose, and duration of metformin treatment and associated pathological conditions. By scrutinizing the available literature on animal and human studies for metformin and brain function, we expect to shed light on the potential impact of metformin on cognition across age, sex, and pathological conditions. This review aims to provide readers with a broader insight of (a) how metformin differentially affects cognition and (b) why there is a need for more translational and clinical studies examining multifactorial interactions. The outcomes of such comprehensive studies will streamline precision medicine practices, avoiding “fit for all” approach, and optimizing metformin use for longevity benefit irrespective of hyperglycemia.

Original languageEnglish
JournalGeroScience
DOIs
StateAccepted/In press - 1 Jan 2020

Fingerprint

Metformin
Cognition
Hyperglycemia
Precision Medicine
Type 2 Diabetes Mellitus
Therapeutics
Clinical Trials

Keywords

  • Age
  • Brain function
  • Cognition
  • Diabetes
  • Gender
  • Metformin
  • Sex

Cite this

@article{9d32687cee0347a3be6e299b73b4b889,
title = "Metformin and cognition from the perspectives of sex, age, and disease",
abstract = "Metformin is the safest and the most widely prescribed first-line therapy for managing hyperglycemia due to different underlying causes, primarily type 2 diabetes mellitus. In addition to its euglycemic properties, metformin has stimulated a wave of clinical trials to investigate benefits on aging-related diseases and longevity. Such an impact on the lifespan extension would undoubtedly expand the therapeutic utility of metformin regardless of glycemic status. However, there is a scarcity of studies evaluating whether metformin has differential cognitive effects across age, sex, glycemic status, metformin dose, and duration of metformin treatment and associated pathological conditions. By scrutinizing the available literature on animal and human studies for metformin and brain function, we expect to shed light on the potential impact of metformin on cognition across age, sex, and pathological conditions. This review aims to provide readers with a broader insight of (a) how metformin differentially affects cognition and (b) why there is a need for more translational and clinical studies examining multifactorial interactions. The outcomes of such comprehensive studies will streamline precision medicine practices, avoiding “fit for all” approach, and optimizing metformin use for longevity benefit irrespective of hyperglycemia.",
keywords = "Age, Brain function, Cognition, Diabetes, Gender, Metformin, Sex",
author = "Kiran Chaudhari and Reynolds, {Conner D.} and Yang, {Shao Hua}",
year = "2020",
month = "1",
day = "1",
doi = "10.1007/s11357-019-00146-3",
language = "English",
journal = "GeroScience",
issn = "2509-2715",
publisher = "Springer International Publishing AG",

}

Metformin and cognition from the perspectives of sex, age, and disease. / Chaudhari, Kiran; Reynolds, Conner D.; Yang, Shao Hua.

In: GeroScience, 01.01.2020.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Metformin and cognition from the perspectives of sex, age, and disease

AU - Chaudhari, Kiran

AU - Reynolds, Conner D.

AU - Yang, Shao Hua

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Metformin is the safest and the most widely prescribed first-line therapy for managing hyperglycemia due to different underlying causes, primarily type 2 diabetes mellitus. In addition to its euglycemic properties, metformin has stimulated a wave of clinical trials to investigate benefits on aging-related diseases and longevity. Such an impact on the lifespan extension would undoubtedly expand the therapeutic utility of metformin regardless of glycemic status. However, there is a scarcity of studies evaluating whether metformin has differential cognitive effects across age, sex, glycemic status, metformin dose, and duration of metformin treatment and associated pathological conditions. By scrutinizing the available literature on animal and human studies for metformin and brain function, we expect to shed light on the potential impact of metformin on cognition across age, sex, and pathological conditions. This review aims to provide readers with a broader insight of (a) how metformin differentially affects cognition and (b) why there is a need for more translational and clinical studies examining multifactorial interactions. The outcomes of such comprehensive studies will streamline precision medicine practices, avoiding “fit for all” approach, and optimizing metformin use for longevity benefit irrespective of hyperglycemia.

AB - Metformin is the safest and the most widely prescribed first-line therapy for managing hyperglycemia due to different underlying causes, primarily type 2 diabetes mellitus. In addition to its euglycemic properties, metformin has stimulated a wave of clinical trials to investigate benefits on aging-related diseases and longevity. Such an impact on the lifespan extension would undoubtedly expand the therapeutic utility of metformin regardless of glycemic status. However, there is a scarcity of studies evaluating whether metformin has differential cognitive effects across age, sex, glycemic status, metformin dose, and duration of metformin treatment and associated pathological conditions. By scrutinizing the available literature on animal and human studies for metformin and brain function, we expect to shed light on the potential impact of metformin on cognition across age, sex, and pathological conditions. This review aims to provide readers with a broader insight of (a) how metformin differentially affects cognition and (b) why there is a need for more translational and clinical studies examining multifactorial interactions. The outcomes of such comprehensive studies will streamline precision medicine practices, avoiding “fit for all” approach, and optimizing metformin use for longevity benefit irrespective of hyperglycemia.

KW - Age

KW - Brain function

KW - Cognition

KW - Diabetes

KW - Gender

KW - Metformin

KW - Sex

UR - http://www.scopus.com/inward/record.url?scp=85077562748&partnerID=8YFLogxK

U2 - 10.1007/s11357-019-00146-3

DO - 10.1007/s11357-019-00146-3

M3 - Review article

C2 - 31897861

AN - SCOPUS:85077562748

JO - GeroScience

JF - GeroScience

SN - 2509-2715

ER -